Read More

Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility

Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by Oaktree Capital Management, L.P. ("Oaktree") have extended to Mesoblast the availability of up to an additional US$30.0 million of its US$90 million five year facility subject to achieving certain milestones on or before September 30, 2023.

MESO

Read More

AMC Entertainment Holdings, Inc. Announces $110M Equity Capital Raise, A $100M Debt For Equity Exchange, And A Proposed Vote To Convert AMC Preferred Equity Units Into AMC Common Shares And Implement A Reverse Stock Split

Raises $110 million of new equity capital through the sale of APE units to Antara Capital, LP ("Antara") at a weighted average price of $0.660 per share. The APE closing price on the NYSE

AMC

Read More

Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment

Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to CEO Adi Zuloff-Shani.

CMND